secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115245
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M
--------------------------------------------------------------------------------

- Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.
- Total revenue $28.1M: TAVALISSE $24.5M (+27% YoY), REZLIDHIA $2.7M, collaboration $1.0M.
- Cash and short-term investments $62.4M at Sep 30, 2023 vs $58.2M at Dec 31, 2022.
- Phase 1b R289 (IRAK1/4 inhibitor) in LR-MDS enrolling third cohort; preliminary data expected mid-2024.
- NECTAR trial fostamatinib arm ceased enrollment per DSMB recommendation; no safety concerns identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/tm2329984d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer